03 August 2021 | News
GenScript will provide the mutant libraries construction to Allozymes for their downstream applications across various industries including pharmaceuticals, cosmetics and food & beverage
Photo Credit: Freepik
GenScript Biotech Corporation has collaborated with Allozymes, a synthetic biology company transforming ingredient manufacturing by unlocking protein engineering potential through groundbreaking technologies. In this partnership, GenScript will provide the mutant libraries construction to Allozymes for their downstream applications across various industries including pharmaceuticals, cosmetics and food & beverage.
Under the agreement, GenScript will leverage strong expertise in de novo gene synthesis capabilities and with the cutting-edge semiconductor-based oligo synthesis technology to offer precise control over each synthesized variant to achieve a diverse and fully covered mutant library with the unbiased distribution.
This precise and rational approach can save valuable target screening time, speed up discovery workflow and reduce overall downstream expenses. Together with Allozymes's patented screening platform, this partnership is expected to achieve significant breakthroughs in protein engineering research.
"At Allozymes we are building the next generation of protein engineering platform, the fastest in kind, in Singapore. The partnership with GenScript will accelerate our path and move us forward to reach our goal faster," said Dr. Peyman Salehian, CEO and co-founder of Allozymes.
GenScript is playing a major role in Singapore's bio-industry and has provided tailored support to the local researchers and developed new clients, Allozymes is one of them.